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Abstract
Background: Enhanced recovery after surgery (ERAS) programs typically utilizes multi-modal analgesia to reduce
perioperative opioid consumption. Systemic lidocaine is used in several of these ERAS algorithms and has been
shown to reduce opioid use after colorectal surgery. However it is unclear how much the other components of
an ERAS protocol contribute to the final outcome. Using a noninferiority analysis we sought to assess the role of
perioperative lidocaine in an ERAS program for colorectal surgery, using pain and opioid consumption as outcomes.
Methods: We conducted a retrospective review of patients who had received intravenous lidocaine perioperatively
during colorectal surgery. We matched them with patients who were managed using a multi-component ERAS
protocol, which included perioperative lidocaine. We tested a joint hypothesis of noninferiority of lidocaine infusion
to ERAS protocol in postoperative pain scores and opioid consumption. We assigned a noninferiority margin of 1
point (on an 11-point numerical rating scale) difference in pain and a ratio [mean (lidocaine) / mean (ERAS)] of 1.2
in opioid consumption, respectively.
Results: Fifty-two patients in the lidocaine group were matched with patients in the ERAS group. With regards to
opioid consumption, in the overall [1.68 (1.43–1.98)] [odds ratio (95% confidence interval)] analysis and on
postoperative day (POD) 1 [2.38 (1.74–3.31)] lidocaine alone was inferior to multi-modal analgesia. On POD 2 and
beyond, although the mean odds ratio for opioid consumption was 1.43 [1.43 (1.17–1.73)], the lower limit extended
beyond the pre-defined cut-off of 1.2, rendering the outcome inconclusive. For pain scores lidocaine is non-inferior
to ERAS [-0.17 (-1.08–0.74)] on POD 2 and beyond. Pain scores on POD 1 and in the overall cohort were
inconclusive based on the noninferiority analysis.
Conclusions: The addition of a multi-component ERAS protocol to intravenous lidocaine incrementally reduces
opioid consumption, most evident on POD 1. For pain scores the data is inconclusive on POD 1, however on POD
2 and beyond lidocaine alone is non-inferior to an ERAS program with lidocaine. Opioid-related complications,
including return of bowel function, were not different between the groups despite reduced opioid use in the
ERAS group.
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Background
Enhanced Recovery After Surgery (ERAS) protocols
are evidence-based algorithms first described by Kehlet
almost two decades ago [1] ERAS protocols have im-
proved patient satisfaction and outcomes with a concomi-
tant reduction in perioperative opioid use [2, 3].
Enhanced recovery protocols typically utilize multi-
modal analgesia to reduce perioperative opioid use.
Whereas the benefits of multi-modal analgesic approaches
are well demonstrated, it is less clear which components
are essential and which have little effect on outcome. As
each component adds some degree of work, cost and
potential risk, it is important to define how each compo-
nent contributes to pain management.
Intravenous lidocaine has gained increasing popularity
over the last decade [4–6]. Systemic lidocaine has anal-
gesic, anti-hyperalgesic and anti-inflammatory properties,
making it a virtually ideal agent for pain management dur-
ing the perioperative period [7]. The short- and long-term
benefits of lidocaine have been demonstrated across a
variety of surgical procedures including colorectal, breast
and spine surgery [6, 8, 9]. Several meta-analyses have
reported that intravenous lidocaine during abdominal
surgery decreases postoperative pain severity, reduces
opioid consumption and nausea and vomiting, improves
gastrointestinal function and shortens length of hospital
stay [4, 5]. Using a noninferiority analysis we recently
reported that after major abdominal surgery patients who
received intravenous lidocaine had clinically similar pain
scores on postoperative day (POD) 2 and beyond com-
pared with patients receiving epidural analgesia [10].
Given these effects, it can be hypothesized that intra-
venous lidocaine provides the majority of the analgesic
benefits of any ERAS protocol, even if the protocol
contains many additional interventions. If so, those other
components could be eliminated without affecting out-
come, which would likely reduce cost and improves
safety. At our institution we utilized perioperative lido-
caine with opioid-based analgesia for colorectal surgery,
and then implemented an ERAS program that included
perioperative lidocaine but added multi-modal analgesia,
opioid restriction and fluid and activity interventions.
This practice change allowed a comparison between the
two approaches as to pain scores, opioid consumption
and side effects.
We hypothesized that in colorectal surgery perioperative
systemic lidocaine with opioid analgesia is non-inferior to
a full ERAS protocol with regards to the endpoints of
postoperative pain scores and opioid consumption.
Methods
This study was initially performed as a quality improve-
ment project with approval from our local departmental
quality improvement committee. Subsequent approval for
publication of the data was obtained from the Univer-
sity of Virginia institutional review board (HSR #10712)
and the need to obtain consent was waived. The study
period was from January 2013 to June 2015 and in-
cluded all patients who underwent colorectal surgery.
The two cohorts identified were patients who received
perioperative lidocaine with opioid-based postoperative
analgesia (LIDO group) and those who were part of
an ERAS program that included multi-modal analgesia
and perioperative lidocaine, as well as restriction of
intravenous fluids and encouragement of oral fluid intake
and ambulation (ERAS group). Patients were matched
by age (within 5 years), gender and chronic opioid use
(>1 month).
As described in our previous study, we assigned a non-
inferiority margin of 1-point (on an 11-point numerical
rating scale) difference in pain and a ratio [mean (LIDO) /
mean (ERAS)] of 1.2 in opioid consumption [10, 11].
Noninferiority is established when the lower bound of the
95% confidence interval (CI) does not cross the inferiority
margin, whereas the comparison is rendered inconclusive
if the lower bound 95% CI does cross the inferiority
margin [12]. We wished to know if lidocaine alone was no
less effective than an ERAS program; therefore a non-
inferiority analysis, as opposed to a superiority analysis
was conducted.
The primary outcome was patient-reported pain
scores at rest and opioid consumption for the first four
postoperative days or discharge if earlier. Secondary
outcomes include hypotension (defined by any blood
pressure requiring adjusting/holding the pain regimen,
additional fluid administration or administration of
inotropes/vasopressors), patient-reported nausea and
documented vomiting, pruritus, urinary retention re-
quiring catheterization, duration of indwelling urinary
catheterization, time to first ambulation, time to first
bowel movement and duration of hospital stay. The re-
gional anesthesia team monitored the lidocaine infusion
and collected data on patient satisfaction and mental
status.
Anesthetic and analgesic regimen
The anesthetic regimen in both groups included general
anesthesia with endotracheal intubation. The typical induc-
tion agent was propofol with muscle relaxation achieved
with either succinylcholine or rocuronium. Anesthesia was
maintained with either sevoflurane or desflurane. If rever-
sal of neuromuscular blockade was required, neostigmine
and glycopyrrolate were administered.
LIDO group
In the LIDO group, intraoperative opioid administration
was at the discretion of the anesthesiology provider. A
lidocaine infusion was started following induction of
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general anesthesia at a rate of 2–3 mg/min, based on
previous reported dosing regimens [13, 14]. Prior to
transfer to the recovery room the infusion was decreased
to 0.5–1 mg/min. The infusion was continued between
0.5 and 1 mg/min for 2–5 days postoperatively.
Postoperatively, hydromorphone patient-controlled
analgesia (PCA) was commenced at a dose of 0.1 to
0.2 mg hydromorphone per bolus, and opioid-tolerant
patients received 0.3 to 0.4 mg hydromorphone per
bolus; both groups had an 8-min lockout. Patients
who did not receive a PCA were given 0.5 to 1.0 mg
intravenous hydromorphone every hour as needed.
Acetaminophen was administered intravenously ini-
tially with a total dose that did not exceed 4 gram/day.
Acetaminophen was changed to an oral formulation
when oral intake resumed. Oxycodone was started
when oral intake permitted to facilitate transitioning
off the PCA. At this time the lidocaine infusion was
typically discontinued.
ERAS group
In the ERAS group, prior to surgery, patients received
an oral regimen of celecoxib 200 mg (not given to pa-
tient with coronary artery disease), acetaminophen
975 mg and gabapentin 600 mg (Table 1).
The components of the intraoperative multi-modal
analgesia included: (1) Prior to induction of anesthesia, a
single intrathecal dose of preservative free morphine
(100 mcg), (2) ketamine 0.5 mg/kg IV at induction
followed by an infusion at 0.6 mg/kg/h (stopped 45-min
before closure for laparoscopic cases and decreased to
0.3 mg/kg/h in open cases until completion of the case
(3) magnesium 30 mg/kg intravenously at induction, (4)
dexamethasone 4 mg at induction (Table 1).
An intravenous lidocaine infusion was commenced as in
the LIDO group for the perioperative period. Intraopera-
tive intravenous opioid administration was only adminis-
tered following approval of the attending anesthesiologist.
Postoperatively 1 g intravenous acetaminophen was
administered every 6 h after initial dose and every 6 h
subsequently. Oral oxycodone 5 mg, 10 mg and 15 mg
every 4 h as required for mild, moderate and severe pain
respectively was prescribed. No PCA was utilized. Cele-
coxib 100 mg was administered twice daily in patients
without coronary artery disease.
Data collection and synthesis
Perioperative data was collected from the anesthesia infor-
mation system and electronic health record. All opioids
used during the intraoperative and postoperative period
were converted to morphine equivalents for analysis [15].
Intrathecal morphine was converted to oral morphine by
a ratio of 1: 100. A 11-point visual analog scale (VAS) was
used to rate postoperative pain. Hypotension was defined
as any blood pressure that required administration of
fluids, inotropes, or vasopressors or withholding pain
medication. Postoperative nausea was identified as any pa-
tient requiring treatment. Time to ambulation, first bowel
movement or passage of flatus, removal of indwelling
urinary catheter and discharge from hospital were calcu-
lated from the time the patient left the operating room.
Patient satisfaction was measured using a binary variable
(yes/no). Patients were asked regularly about peri-oral
numbness/tingling, dizziness, tinnitus, diplopia, seizures,
arrhythmia, extremity numbness and muscle twitching to
Table 1 Perioperative analgesia regimen in the standard therapy-perioperative lidocaine and enhanced recovery multi-modal
analgesia-perioperative lidocaine group
Perioperative Analgesia Regimen
Standard Therapy-Perioperative Lidocaine ER Multi-Modal Analgesia-Perioperative Lidocaine
Preoperative 1. None 1. Celecoxib 200 mg POc
2. Acetaminophen 975 mg PO
3. Gabapentin 600 mg PO
Intraoperative 1. Intravenous lidocaine 2–3 mg/min
2. Intravenous Opioidsa
3. Intravenous Ketaminea
1. Intravenous lidocaine 2–3 mg/min
2. Single intrathecal dose of preservative free morphine (100 μg)
3. Ketamine 0.5 mg/kg IV at induction followed by an infusion at
0.6 mg/kg/h (stopped 45-min before closure for laparoscopic cases
and decreased to 0.3 mg/kg/h in open cases until completion of
the case
4. Magnesium 30 mg/kg intravenously at induction
5. Dexamethasone 4 mg at induction
6. Intravenous opioidsb
Postoperatively 1. Intravenous lidocaine 0.5–1 mg/min
2. Hydromorphone PCA and oral oxycodone
3. Acetaminophen
1. Intravenous lidocaine 0.5–1 mg/min
2. Celecoxib 100 mg twice daily
3. No opioid PCA
4. Oral oxycodone
5. Acetaminophen
PO-per oral, μg-microgram, mg-milligram
aDiscretion of anesthesiology provider. bAfter approval of attending anesthesiologist.cNot administered to patients with coronary artery disease
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assess for lidocaine toxicity, as is standard for our practice.
Postoperative mental status was assessed using the follow-
ing scale: awake/alert, confused, somnolent, arouses with
simulation, difficult to arouse, or unresponsive.
Power analysis
As we did not foresee the use of the data for the
current study at the time of data collection, an a priori
power analysis was not conducted. The size of the con-
fidence interval provides an indication of the likelihood
of the real effect size being zero or very small. For our
non-inferiority study, the upper limit of the confidence
interval is an estimation of the maximum effect size
supported by the current data.
We feel it is inappropriate to perform post-hoc power
calculations in this setting, because the calculated
power (i.e., “observed” power obtained from the model
estimates) is a function of the p-values of the model
estimates, meaning that post-hoc power analysis does
not provide additional information to the results [16].
In addition, when there is a non-significant finding
(such as the ones in the current study), a higher post-
hoc power provides stronger evidence against the null
hypothesis [17].
Statistical analysis
Normality of data was established using the Shapiro-
Wilk test. Normally distributed data are reported as
mean and SD while non-normally distributed data are
reported as median and 25th-75th interquartile range.
The two primary outcomes (postoperative pain and
opioid consumption) were assessed postoperatively in the
recovery room, and every 12 h for up to 4 days. Mixed-
effects models were used to examine the changes in the
primary outcomes over time, taking into account the
within-individual correlations between assessments.
The mixed-effects model found to be best fit the
changes in the overall postoperative pain scores is:
Y ij ¼ β0 þ β1x1ij þ β2x2ij þ bi0 þ bi1z1ij þ εij
where Yij is the postoperative pain score for observation
j in patient i; x1ij refers to the linear time (number of
days), and x2ij refers to the analgesia group (ERAS vs.
LIDO) fixed effects for observation j in patient i; β0 is
the random intercept for patient i, z1ij is the random
slope for time; and εij is the error for observation j in
patient i. This model indicates that the change in post-
operative pain scores follows a linear trend over time,
with between-patient heterogeneity in initial postopera-
tive pain scores (in recovery room) and the rate of
changes in pain scores across time. The same model was
fitted to the changes in postoperative pain scores POD1
only, and POD2 to POD4.
The mixed-effects model found to be best fit the
changes in the overall postoperative morphine consump-
tion is:
Y ij ¼ β0 þ β1x1ij þ β2x2ij þ β3x3ij þ bi0 þ bi1z1ij þ εij
where Yij is the postoperative morphine consumption
for observation j in patient i; x1ij refers to the linear time
(number of days), x2ij refers to the quadratic (non-linear)
time, and x3ij refers to the analgesia group (ERAS vs.
LIDO) fixed effects for observation j in patient i; β0 is
the random intercept for patient i, z1ij is the random
slope for time; and εij is the error for observation j in pa-
tient i. This model indicates that the change in morphine
consumption follows a non-linear trend over time, with
between-patient heterogeneity in initial postoperative pain
scores (in recovery room) and the rate of changes in pain
scores across time. The same model was fitted to the
changes in postoperative morphine consumption POD1
only. However, the model without the quadratic time fixed
effects was fitted to the changes in postoperative mor-
phine consumption on POD2 to POD4, meaning that the
changes in postoperative morphine consumption POD2
to POD4 follows a linear trend over time.
Fisher’s exact test or Mann-Whitney U test was used
to compare the incidences of each secondary outcome.
All statistical analyses were conducted using the statis-
tical program R version 3.2 (R Core Team (2015). R: A
language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria.
URL https://www.R-project.org/).
Results
Fifty-two patients in the LIDO group were matched
with 52 patients in the ERAS group. Perioperative vari-
ables are shown in Table 2. No significant differences in
demographic and preoperative opioid consumption
were noted. Total intraoperative opioid use was similar
between the groups (LIDO: 18.8 [10.6-27.5] mg vs.
ERAS: 15 [7.50–25] mg, p = 0.14), however significantly
more intravenous opioids were administered in the
lidocaine group while there was more intrathecal opioid
use in the ERAS group. This was primarily related to
the ERAS protocol limiting intravenous administration
of opioids. All patients in the ERAS group received oral
acetaminophen, gabapentin and celecoxib prior to sur-
gery. No patient in the standard group received oral
acetaminophen, gabapentin and celecoxib prior to sur-
gery. Total lidocaine dose was higher in the LIDO
group (LIDO: 2888 [2188-4322] mg versus ERAS: 1557
[959-1992] mg, p = 0.0001), primarily due to the earlier
discharge in the ERAS group. An additional supple-
mentary file titled ‘Database’ reports the raw data in
more detail [see Additional file 1].
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Primary outcome
As previously described, the non-inferiority margin for
pain was defined a priori as a 1-point difference between
the two groups. Mean pain scores are represented in
Fig. 1. Our data demonstrate that for the overall study
period the upper limit 95% confidence interval extends
beyond the 1-point difference (Table 3, Fig. 3), indicating
one can not conclude from the data that lidocaine is
inferior to ERAS group. The pain score for POD 1 is
similar, with the mean difference and 95% confidence
interval 1.16 (0.15–2.18); thus, although the difference
falls within the non-inferiority range, the upper limit CI
extends beyond the 1-point difference (Table 3, Fig. 3a).
For POD 2 and beyond lidocaine is non-inferior to
ERAS [-0.17 (-1.08–0.74)].
For opioid consumption, the non-inferiority limit was
defined a priori as a ratio of mean lidocaine / mean ERAS
of 1.2. Mean opioid use (morphine equivalents) is demon-
strated in Fig. 2. In the overall and POD 1 group lidocaine
was inferior to ERAS for opioid consumption (Table 3,
Fig. 3b). For POD 2 and beyond, although the mean ratio
was 1.43, the lower limit extended beyond the pre-defined
cut-off, rendering the outcome inconclusive.
Secondary outcome
Secondary outcomes are listed in Table 4. There was no
difference noted in the incidence of hypotension and
nausea/vomiting between the groups. There was an in-
creased incidence of pruritus present on POD 2 in the
LIDO group, however this was not evident on POD 3 and
4. In the LIDO group a higher percentage of patients with
either confusion, somnolence, difficulty with arousal or
unresponsive was evident on POD 2 (LIDO: 11.54% vs.
ERAS: 0%, p = 0.03).
Time to ambulation, duration of bladder catheterization
and duration of hospital stay were significantly reduced in
the ERAS group (Table 4). No difference in the time to
first bowel movement was noted between the groups.
Total postoperative lidocaine dose was significantly higher
in LIDO group.
Discussion
Our study demonstrates incremental benefit of adding
the components of a full ERAS protocol (including
multi-modal analgesics) to perioperative lidocaine for
reducing opioid requirements after colorectal surgery.
The opioid-sparing effects are most evident on POD 1
and extend into POD 2 and beyond even though it does
not reach the statistical significance level defined a prior.
Although pain scores tended to be higher in the
LIDO group, the non-inferiority analysis is inconclusive
on POD 1 and in the overall cohort. However, pain
scores demonstrate noninferiority in the standard care-
perioperative lidocaine group on POD 2 and beyond. It








Age (years)a 52.8 (14.6) 53.5 (13) 0.79
Gender (% men)b 50 50 1
BMI (kg/m2)c 26.11 [22.9-29.8] 26.7 [23.6-31] 0.47
Chronic pain (%)b 44 44 1
Preoperative morphine equivalent (mg)c 0 [0-23.3] 0 [0-10] 0.17
Intraoperative
Laparoscopic Procedures n (%) 12 (23%) 27 (52%) 0.004
Total Intraoperative morphine equivalent (mg)c 18.8 [10.6-27.5] 15 [7.50-25] 0.14
Intrathecal Morphine (mg) 0 [0-0] 0.15 [0.1-0.25] 0.0001
Intravenous Fentanyl (μg) 150 [100-250] 0 [0-0] 0.0001
Intravenous Hydromorphone (mg) 1 [0.4-2] 0 [0-0] 0.0001
Ketamine (mg) 0 [0-60.7] 102 [63.8-150.2] 0.0001
Magnesium (mg) 0 [0-0] 2000 [2000-2500] 0.0001
Lidocaine (mg) 494 [379-615] 592 [388-900] 0.13
Postoperative
Lidocaine (mg) 2888 [2188-4322] 1557 [959-1992] 0.0001
aPresented as mean (SD), P value from simple t test
bPresented as frequency, P value from χ2 or Fisher exact test
cPresented as median and (IQR), P value from Mann-Whitney U test
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Fig. 1 Mean and standard error of postoperative NRS pain scores. NRS: Numerical Rating Scale, ERAS: Enhanced Recovery After Surgery
Table 3 Difference in NRS pain scores and opioid consumption
Difference in NRS Pain Scores and Opioid Consumption






(ST − ER) (95% CI)
Δ p-value
Overall 4.7 (2) 4.5 (2) 0.43 (-0.46-1.31) 1 0.1
4.5 [3.0, 6.0] 4.7 [2.7, 6.0]
Day 1 5.23 (2.12) 4.17 (2.10) 1.16 (0.15-2.18) 1 0.62
5.11 [3.65, 6.76] 4.02 [2.60, 5.88]
Day 2 and beyond 4.44 (2.06) 4.70 (2.04) -0.17 (-1.08-0.74) 1 0.006
4.49 [2.66, 6.00] 4.77 [3.40, 6.22]





Mean ST/Mean ER Opioid
Consumption (95% CI)
Overall 52.54 (64.45) 31.22 (36.62) 1.68 (1.43-1.98) 1.2 <0.0001
30.20 [17.32, 54.94] 22.91 [9.77, 40.39]
Day 1 43.77 (54.02) 18.43 (28.83) 2.38 (1.74-3.31) 1.2 <0.0001
25.18 [13.93, 46.54] 9.95 [1.95, 23.78]
Day 2 and beyond 57.03 (72.42) 39.93 (40.58) 1.43 (1.17-1.73) 1.2 0.8
27.46 [16.15, 71.43] 28.42 [15.98, 47.68]
Data presented as mean (SD) and median [IQR]
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Fig. 2 Mean and standard error of opioid (morphine equivalent) consumption. ERAS: Enhanced Recovery After Surgery
Fig. 3 Noninferiority margins for pain scores (a) and opioid consumption (b). Squares represent the mean and the whiskers represent the 95%
confidence interval. ERAS: Enhanced Recovery After Surgery
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is important to note these findings were present despite
there being significantly more open (and presumably
more painful) procedures in the LIDO group (23% vs.
52%, p = 0.004).
The reduced time to ambulation, duration of urinary
catheterization and hospital stay noted in the ERAS
group are related to standardized goals for early ambula-
tion and removal of urinary catheters.
ERAS programs are designed to reduce opioid con-
sumption, opioid-related complications (nausea, ileus,
etc.) and to encourage early mobilization. It is import-
ant to note that the early ambulation noted in the
ERAS group (ERAS: 20 [13.50, 25.75] hrs vs. LIDO:
44.5 [22, 65.5] hrs) potentially may have contributed to
increase pain and opioid consumption, which was obvi-
ated by intraoperative multi-modal analgesia (Table 1).
Table 4 Secondary outcomes
Standard Therapy-Perioperative Lidocaine ER Multi-Modal Analgesia-Perioperative Lidocaine P value
Hypotensiona
POD 1 0 (52); 0% 1 (52); 1.92% 1
POD 2 0 (52); 0% 0 (49); 0% -
POD 3 0 (40); 0% 0 (10); 0% -
POD 4 1 (23); 4.35% 0 (5); 0% 1
Nausea and Vomitinga
POD 1 11 (52); 21.15% 6 (52); 11.54% 0.29
POD 2 16 (52); 30.77% 7 (49); 14.29% 0.06
POD 3 9 (40); 22.50% 5 (10); 50% 0.12
POD 4 8 (23); 34.78% 2 (5); 40% 1
Pruritisa
POD 1 5 (52); 9.62% 2 (52); 0.04% 0.44
POD 2 13 (52); 25% 2 (49); 4.08% 0.004
POD 3 6 (40); 15% 1 (10); 10% 1
POD 4 2 (23); 8.70% 0 (5); 0% 1
Mental status: not awake or alerta
POD 1 4 (52); 7.69% 2 (52); 0.04% 0.68
POD 2 6 (52); 11.54% 0 (49); 0% 0.03
POD 3 3 (40); 7.50% 0 (10); 0% 1
POD 4 0 (23); 0% 0 (5); 0% -
Urinary retentiona
POD 1 1 (52); 1.92% 6 (52); 0.12% 0.11
POD 2 1 (52); 1.92% 3 (49); 6.12% 0.35
POD 3 31 (40); 77.50% 6 (10); 60% 0.42
POD 4 0 (22); 0% 1 (5); 20% 0.19
Patient Satisfaction: yesa
POD 1 34 (52); 65.38% 38 (52); 73.08% 0.52
POD 2 42 (52); 80.77% 40 (49); 81.63% 1
POD 3 31 (40); 77.50% 6 (10); 60% 0.42
POD 4 19 (23); 82.61% 1 (5); 20% 0.01
Time to ambulation (hr)bc 44.50 [22, 65.50] 20 [13.50, 25.75] < .001
Duration of urine catheter (hr)bc 43.50 [25.75, 67.50] 27 [20, 42] 0.006
Time to bowel movement (hr)bc 40 [18, 71.50] 41.25 [28.38, 51] 0.63
Duration hospital stay (hr)bc 146 [96.75, 288] 72.25 [66.75, 114.12] < .001
aPresented as frequency, P value from χ2 or Fisher exact tests
bPresented as median and (IQR), P value from Mann-Whitney U test
cAll these measurements calculated from the time the patient left the operating room
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Based on our results the addition of this multi-modal
analgesic regimen to perioperative lidocaine is associated
with a reduction in opioid consumption most evident on
POD 1, but interestingly not with a decrease in opioid-
related side effects.
The combination of intraoperative intrathecal mor-
phine, ketamine and magnesium likely contributed to
the significant reduction in opioid requirements noted
on POD 1 (LIDO: 25.18 [13.93, 46.54] mg vs. ERAS:
9.95 [1.95, 23.78] mg). This effect is less striking on
POD 2 and beyond (LIDO: 27.46 [16.15, 71.43] mg vs.
ERAS: 28.42 [15.98, 47.68] mg) and probably reflects the
waning effect of neuraxial morphine and N-methyl-D-
aspartate (NMDA) antagonist.
A single dose of intrathecal morphine prior to surgery
reduces postoperative enteral and parenteral opioid re-
quirements after abdominal surgery. The duration of
opioid-sparing depends on the type of opioid and the
dose administered. Reported benefits of a single dose of
intrathecal morphine are evident up to 24 h after admin-
istration [18, 19]. These findings are consistent with our
data, which demonstrates significant opioid sparing ef-
fect in the ERAS group on POD 1. Complications of
intrathecal morphine such as pruritus, respiratory de-
pression and nausea/vomiting are not evident in our
study, with no clinically significant morbidity noted in
the group that received intrathecal morphine (Table 4).
Furthermore, alterations in mental status, which would
be a surrogate marker of significant respiratory depres-
sion, were not different between the groups (LIDO:
7.69% vs. ERAS: 0.04%, p = 0.11] on POD 1.
The inclusion of ketamine also likely played a role in
reducing postoperative opioid use. In abdominal surgery
sub-anesthetic doses of ketamine modulate opioid-
induced hyperalgesia via the NMDA receptor reducing
postoperative pain and opioid consumption [20, 21]. The
anti-nociceptive benefits of low-dose ketamine are evi-
dent up to 24 h after surgery. Anti-nociceptive effects
mediated via NMDA antagonism are more pronounced
when a second NMDA antagonist is added to ketamine.
Magnesium, an endogenous voltage-dependent NMDA
receptor-channel blocker, demonstrates synergism with
ketamine. In a rat model of acute nociception, the com-
bination of magnesium and ketamine was more effective
in reducing pain than either drug alone [22, 23].
Although our data demonstrates reduction in opioid use
in the ERAS group, opioid-related complications were not
significantly different between the two groups. Somewhat
surprisingly, return of bowel function, a major side effect
of opioids, was not different (LIDO: 40 [18, 71.50] h vs.
ERAS 41.3[28.38, 51] h, p = 0.63) between the two groups.
The opioid consumption and pain scores profile re-
ported here are similar to findings presented in our pre-
vious study comparing lidocaine to epidural analgesia
for major abdominal surgery [10]. In that study intraven-
ous lidocaine was inferior to epidural for opioid con-
sumption (overall, POD 1 and POD 2 beyond) with pain
scores demonstrating non-inferiority on POD 2 and
beyond.
There are several limitations of this study. In the
LIDO group no pre-defined algorithm for opioid ad-
ministration was utilized with opioid administration
solely determined by the clinical team managing the pa-
tient. This variability may have influenced our results.
We had a small study size, which reduces the chance of
detecting a true effect or reduces the likelihood that a
statistically significant result reflects a true effect. This
was a single-center study investigating an institutional
specific ERAS program, therefore our results may not
be translatable to other institutions using different
ERAS programs. Finally this was retrospective chart
review and the possibility of misclassification bias or
incorrectly coded data in the electronic medical record
cannot be excluded.
As reported in our previous study, there are no stan-
dardized criteria for non-inferiority analysis [10]. We uti-
lized a noninferiority margin of 1-point (on an 11-point
numerical rating scale) difference in pain and a ratio
[mean (lidocaine)/ mean (ERAS)] of 1.2 in opioid con-
sumption for consistent reporting between our studies.
Changing the noninferiority margin can potentially alter
the outcomes of our results. Finally, we acknowledge the
limitation of the lack of an a priori power analysis in the
current study; however, power analysis for future studies
can be performed with the current data.
Conclusions
In conclusion, our data suggest that ERAS protocols that
include intraoperative intrathecal opioids and non-
opioid analgesics have a distinct opioid-sparing effect
within the first 24 h compared to lidocaine alone. We
suggest that a combination of intraoperative protoco-
lized pain management with postoperative continuation
of intravenous lidocaine has distinct benefits on pain
scores and opioid use for colorectal surgery.
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